Lincoln Capital Corp Invests $263,000 in Eli Lilly and Company (NYSE:LLY)

Lincoln Capital Corp purchased a new position in Eli Lilly and Company (NYSE:LLY) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 338 shares of the company’s stock, valued at approximately $263,000.

A number of other hedge funds also recently modified their holdings of the stock. Vanguard Capital Wealth Advisors raised its holdings in shares of Eli Lilly and Company by 3.7% in the 1st quarter. Vanguard Capital Wealth Advisors now owns 565 shares of the company’s stock worth $440,000 after purchasing an additional 20 shares during the period. Thrive Wealth Management LLC raised its holdings in Eli Lilly and Company by 30.3% during the 1st quarter. Thrive Wealth Management LLC now owns 1,554 shares of the company’s stock valued at $1,209,000 after acquiring an additional 361 shares during the period. Bouvel Investment Partners LLC raised its holdings in Eli Lilly and Company by 55.8% during the 1st quarter. Bouvel Investment Partners LLC now owns 6,459 shares of the company’s stock valued at $5,025,000 after acquiring an additional 2,313 shares during the period. Towerpoint Wealth LLC raised its holdings in Eli Lilly and Company by 0.9% during the 1st quarter. Towerpoint Wealth LLC now owns 4,264 shares of the company’s stock valued at $3,317,000 after acquiring an additional 38 shares during the period. Finally, ERn Financial LLC raised its holdings in Eli Lilly and Company by 3.7% during the 1st quarter. ERn Financial LLC now owns 1,414 shares of the company’s stock valued at $1,100,000 after acquiring an additional 50 shares during the period. Institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 2,052 shares of the company’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $809.00, for a total transaction of $1,660,068.00. Following the completion of the transaction, the insider now directly owns 98,554,195 shares of the company’s stock, valued at $79,730,343,755. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, EVP Johna Norton sold 7,056 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the completion of the transaction, the executive vice president now directly owns 25,428 shares of the company’s stock, valued at $20,835,194.64. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 2,052 shares of the company’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $809.00, for a total transaction of $1,660,068.00. Following the transaction, the insider now directly owns 98,554,195 shares of the company’s stock, valued at $79,730,343,755. The disclosure for this sale can be found here. Insiders sold a total of 789,704 shares of company stock worth $672,385,964 over the last three months. Company insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

LLY has been the topic of a number of analyst reports. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. JPMorgan Chase & Co. boosted their target price on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a report on Wednesday, May 1st. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Citigroup boosted their target price on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a report on Tuesday, April 2nd. Finally, Truist Financial reaffirmed a “buy” rating and issued a $1,000.00 price target (up previously from $892.00) on shares of Eli Lilly and Company in a report on Tuesday. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $812.72.

Eli Lilly and Company Price Performance

NYSE:LLY traded up $4.70 during midday trading on Friday, hitting $913.74. The company had a trading volume of 594,200 shares, compared to its average volume of 2,914,721. Eli Lilly and Company has a 52-week low of $434.34 and a 52-week high of $915.54. The stock’s fifty day moving average price is $807.55 and its 200-day moving average price is $735.35. The company has a market capitalization of $868.43 billion, a PE ratio of 134.57, a P/E/G ratio of 1.97 and a beta of 0.36. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The business had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. During the same period in the prior year, the business posted $1.62 earnings per share. The company’s revenue was up 26.0% on a year-over-year basis. As a group, research analysts expect that Eli Lilly and Company will post 13.76 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be given a dividend of $1.30 per share. The ex-dividend date is Thursday, August 15th. This represents a $5.20 annualized dividend and a yield of 0.57%. Eli Lilly and Company’s payout ratio is 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.